Literature DB >> 32852670

Characteristics and risk factors of deep vein thrombosis in hemiplegic, healthy and bilateral limbs of hemiplegic patients: a 10-year retrospective study.

Feng Liang1, Min Chao2, Jue-Bao Li1, Xiang-Ming Ye3.   

Abstract

Deep vein thrombosis (DVT) in hemiplegic patients mainly affects hemiplegic limbs, DVT can also occur only in healthy limbs, and some hemiplegic patients have DVT in both limbs. Characteristics and risk factors of DVT in hemiplegic, healthy, and bilateral limbs are unknown. To describe the proportion, risk factors, extent, and timing of DVT in hemiplegic, healthy and bilateral limbs. A 10-year retrospective review of consecutive patients was performed. DVT affected hemiplegic limbs in 34 (62%), healthy limbs in 11 (20%), and was bilateral in 10 (18%). DVT was more likely to develop in healthy limbs of hemiplegic patients without surgery (odds ratio (OR) 0.022; 95% confidence interval (CI) 0.001-0.922), and without diabetes (OR 0.023, 95% CI 0.001-0.853). Among the veins at the level of which DVT occurred, intermuscular veins represented 20 (45%) in hemiplegic, 5 (37%) in healthy, and 6 (74%) in bilateral limbs. The median time that DVT occurred after hemiplegia onset was 18 days (interquartile range [IQR] 9-79) in hemiplegic, 17 days (IQR 10-56) in healthy, and 21 days (IQR 8-27) in bilateral limbs. Early and effective prevention of DVT after surgery and optimal management of diabetes may reduce the risk of DVT in bilateral limbs. It's important to prevent proximal extension of calf vein DVT. DVT prophylaxis should be started early and continued for at least 3 weeks after hemiplegia onset.

Entities:  

Keywords:  Bilateral limbs; Deep vein thrombosis; Healthy limbs; Hemiplegia; Hemiplegic limbs; Retrospective study

Year:  2020        PMID: 32852670     DOI: 10.1007/s11239-020-02254-w

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  19 in total

Review 1.  Prevention of venous thromboembolism.

Authors:  W H Geerts; J A Heit; G P Clagett; G F Pineo; C W Colwell; F A Anderson; H B Wheeler
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  The timing, extent, progression and regression of deep vein thrombosis in immobile stroke patients: observational data from the CLOTS multicenter randomized trials.

Authors:  M Dennis; N Mordi; C Graham; P Sandercock
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

Review 3.  Prevention of venous thromboembolism after stroke.

Authors:  Richard L Harvey
Journal:  Top Stroke Rehabil       Date:  2003       Impact factor: 2.119

4.  Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study.

Authors:  Sébastien Weill-Engerer; Sylvie Meaume; Amina Lahlou; François Piette; Olivier Saint-Jean; Annick Sachet; Jean-Yves Beinis; Claude Gallinari; Anne-Sophie Grancher; Jean-Pierre Vincent; Henri Naga; Joel Belmin; Rosella Salvatore; Marie Kazes; Eric Pautas; André Boiffin; Jean-Bernard Piera; Monique Duviquet; David Knafo; Andrée Piau; Dragoslav Miric; Alain Jean; Valérie Bellamy; Olivier Tissandier; Alain-Ferdinand Le Blanche
Journal:  J Am Geriatr Soc       Date:  2004-08       Impact factor: 5.562

5.  Mechanisms and timing of deaths from cerebral infarction.

Authors:  J V Bounds; D O Wiebers; J P Whisnant; H Okazaki
Journal:  Stroke       Date:  1981 Jul-Aug       Impact factor: 7.914

6.  Deep venous thrombosis in stroke patients during rehabilitation phase.

Authors:  Yukihiro Hara
Journal:  Keio J Med       Date:  2008-12

7.  Deep venous thrombosis after acute intracerebral hemorrhage.

Authors:  Toshiyasu Ogata; Masahiro Yasaka; Yoshiyuki Wakugawa; Tooru Inoue; Setsuro Ibayashi; Yasushi Okada
Journal:  J Neurol Sci       Date:  2008-06-13       Impact factor: 3.181

Review 8.  The epidemiology of venous thromboembolism.

Authors:  John A Heit; Frederick A Spencer; Richard H White
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

9.  Circulating total bilirubin and risk of non-alcoholic fatty liver disease in the PREVEND study: observational findings and a Mendelian randomization study.

Authors:  Setor K Kunutsor; Monika Frysz; Niek Verweij; Lyanne M Kieneker; Stephan J L Bakker; Robin P F Dullaart
Journal:  Eur J Epidemiol       Date:  2019-11-26       Impact factor: 8.082

Review 10.  Basic mechanisms and pathogenesis of venous thrombosis.

Authors:  Charles T Esmon
Journal:  Blood Rev       Date:  2009-09       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.